Cue Biopharma (NASDAQ:CUE) Stock Price Down 3.8% – What’s Next?

Cue Biopharma, Inc. (NASDAQ:CUE) shares were down 3.8% during trading on Monday . The company traded as low as $1.25 and last traded at $1.27. Approximately 93,309 shares traded hands during mid-day trading, a decline of 69% from the average daily volume of 298,050 shares. The stock had previously closed at $1.32.

Cue Biopharma Stock Performance

The company has a fifty day moving average price of $1.29 and a two-hundred day moving average price of $1.12. The firm has a market cap of $80.45 million, a price-to-earnings ratio of -1.41 and a beta of 1.66. The company has a debt-to-equity ratio of 0.05, a current ratio of 2.22 and a quick ratio of 2.22.

Insider Buying and Selling at Cue Biopharma

In other Cue Biopharma news, CEO Daniel R. Passeri purchased 30,000 shares of the firm’s stock in a transaction on Monday, December 16th. The shares were purchased at an average price of $1.03 per share, for a total transaction of $30,900.00. Following the completion of the transaction, the chief executive officer now owns 164,578 shares in the company, valued at $169,515.34. This represents a 22.29 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 12.26% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Cue Biopharma

Several large investors have recently modified their holdings of the stock. Navalign LLC purchased a new stake in shares of Cue Biopharma during the fourth quarter valued at $27,000. Texas Capital Bank Wealth Management Services Inc acquired a new stake in Cue Biopharma during the 4th quarter worth about $36,000. LPL Financial LLC lifted its stake in Cue Biopharma by 139.5% during the fourth quarter. LPL Financial LLC now owns 42,929 shares of the company’s stock valued at $47,000 after buying an additional 25,004 shares in the last quarter. XTX Topco Ltd boosted its holdings in shares of Cue Biopharma by 69.8% in the fourth quarter. XTX Topco Ltd now owns 46,973 shares of the company’s stock worth $51,000 after buying an additional 19,308 shares during the period. Finally, Jane Street Group LLC increased its position in shares of Cue Biopharma by 145.9% in the fourth quarter. Jane Street Group LLC now owns 63,767 shares of the company’s stock worth $70,000 after acquiring an additional 37,832 shares in the last quarter. 35.04% of the stock is owned by institutional investors.

About Cue Biopharma

Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer.